Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma
Radiation Research · 22.11.2023 · 200 (6) · 587-592
DOI: 10.1667/rade-23-00126.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Research, erschienen am 22.11.2023. Verfasst von Kevin J Tu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina 27710. Hauptthemen laut MEDLINE: Medulloblastoma, Brain Neoplasms, Radiation Injuries, Cerebellar Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Medulloblastoma is the most common malignant brain tumor of children. Although standard of care radiotherapy for pediatric medulloblastoma (PM) can lead to long-term remission or cure in many patients, it can also cause life-long cognitive impairment and other adverse effects. The pathophysiological mechanisms involved in radiation-induced cerebral damage are incompletely understood, and their elucidation may lead to interventions that mitigate radiation toxicity. To explore the mechanisms of radiation-induced cerebral damage, transgenic mouse models of PM and non-tumor-bearing controls were exposed to radiation doses that ranged from 0 to 30 Gy. Between 0–20 Gy, a significant dose-dependent reduction in tumor-associated hydrocephalus and increase in overall survival were observed. However, at 30 Gy, hydrocephalus incidence increased and median overall survival fell to near-untreated levels. Immunohistochemistry revealed that both tumor-bearing and non-tumor-bearing mice treated with 30 Gy of radiation had significantly more reactive astrocytes and microvascular damage compared to untreated controls. This effect was persistent across mice that were given 1 and 2 weeks of recovery time after irradiation. Our data suggest that radiation therapy promotes neural death by inducing long-term neuroinflammation in PM, suggesting radiation delivery methods that limit inflammation may be effective at widening the therapeutic window of radiation therapy in PM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina 27710.
- Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland 21044.
- Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom CB2 0RE.
- Department of Radiation Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
- Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, ON M5G 2M9, Canada.
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Tu, K. J., Stewart, C. E., Williams, N. T., Ma, Y., Luo, L., Ghosh, D., Weidenhammer, L. B., Floyd, S. R., Fan, Y., Kirsch, D. G., Oldham, M., & Reitman, Z. J. (2023). Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma. Radiation Research, 200(6), 587-592. https://doi.org/10.1667/rade-23-00126.1
Vancouver
Tu KJ, Stewart CE, Williams NT, Ma Y, Luo L, Ghosh D, et al. Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma. Radiation Research. 2023;200(6):587-592. doi:10.1667/rade-23-00126.1
BibTeX
@article{Tu2023,
author = {Tu, Kevin J and Stewart, Connor E and Williams, Nerissa T and Ma, Yan and Luo, Lixia and Ghosh, Debosir and Weidenhammer, Loren B and Floyd, Scott R and Fan, Yi and Kirsch, David G and Oldham, Mark and Reitman, Zachary J},
title = {Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma},
journal = {Radiation Research},
year = {2023},
volume = {200},
number = {6},
pages = {587--592},
doi = {10.1667/rade-23-00126.1}
}
EUVIMED